Vykat XR Post-Marketing Deaths Threaten $2.9B Acquisition Value as Mechanism-Based Toxicity Resurfaces

Neurocrine's Prader-Willi Drug Linked to Post-Marketing Deaths

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences' Vykat XR, an approved treatment for the rare genetic disease Prader-Willi syndrome. These post-marketing surveillance reports, recorded by the FDA’s Adverse Events Monitoring System, include instances of swelling, respiratory, and heart complications. Neurocrine, which acquired Vykat XR through a $2.9 billion acquisition of Soleno Therapeutics, is in close contact with the FDA and patient advocacy groups. BMO Capital Markets noted a 2% drop in Neurocrine's stock and anticipates potential physician caution and regulatory scrutiny, while the Prader-Willi Syndrome Association (PWSA) urges informed prescribing, emphasizing the complex medical histories of PWS patients.

• Clinicians have raised alarms regarding a new safety signal for Neurocrine Biosciences' Vykat XR, a drug approved for Prader-Willi syndrome. The FDA’s Adverse Events Monitoring System has recorded seven deaths and 100 serious adverse events, including swelling, respiratory, and heart complications, since the drug entered the market last year. Neurocrine is actively engaging with the FDA, patient advocacy groups, and prescribers to address these post-marketing surveillance findings.
• Following the safety reports, Neurocrine's stock experienced a 2% decline. BMO Capital Markets highlighted that these serious events were not apparent in Vykat's clinical trials, which only showed low-severity swelling. The firm anticipates that increased physician caution in prescribing and potential regulatory scrutiny could impact the product's uptake and launch trajectory in the coming quarters, despite acknowledging the drug's compelling risk-benefit profile for a serious disease.
• The Prader-Willi Syndrome Association (PWSA) issued a warning to patients and caregivers but also stressed the importance of context and further research. While acknowledging the concerning reports, PWSA noted that the events are not yet definitively linked to Vykat XR and involve patients with complex medical histories, who inherently face a higher risk of serious respiratory and cardiac complications throughout their lives. The association advocates for 'informed prescribing' rather than withdrawal of the drug.

Addressing the Unmet Needs in Prader-Willi Syndrome

Current treatment approaches for Prader-Willi syndrome (PWS) face significant gaps across multiple clinical domains, from metabolic control to respiratory management. These limitations collectively underscore the complexity of delivering comprehensive care to this patient population.

• Hyperphagia and obesity management remain largely non-pharmacological: No established medical therapy effectively addresses the pathological food-seeking behavior central to PWS. Management relies on environmental controls — including locked kitchens and continuous supervision — combined with strict caloric restriction. Paradoxically, the resulting caloric deficit can intensify the hunger drive, and associated behaviors such as food hoarding, stealing, eating inedibles, and deceptive eating impose substantial burden on both patients and caregivers.

• Surgical intervention for obstructive sleep apnea (OSA) yields inconsistent outcomes: Upper airway surgery alone is insufficient to reliably resolve OSA in PWS patients. In a five-patient study of adenoidectomy or adenotonsillectomy, median AHI decreased from 16.4 to 4.4, yet the change did not reach statistical significance (p=0.274). Improvements in mean O₂ and nadir O₂ saturation were similarly non-significant. Furthermore, spontaneous OSA resolution is rare; a 4-year follow-up of 22 pediatric patients found only two cases of spontaneous resolution, calling into question watchful waiting as a viable management strategy.

• Growth hormone (GH) therapy carries respiratory safety concerns: GH use in PWS has been associated with sudden death, with evidence suggesting it may exacerbate pre-existing gas-exchange deficiencies through three mechanisms: stimulation of adenotonsillar hypertrophy, increased basal metabolic rate elevating oxygen demand, and normalization of hydration status augmenting volume load. As a result, current guidance recommends OSA evaluation and, where indicated, adenotonsillectomy or CPAP initiation prior to commencing GH therapy, with reassessment for residual airway obstruction before proceeding.

• Mechanistic understanding of hyperphagia remains inadequate: The hypothalamic dysfunction underlying hyperphagia in PWS is poorly characterized at a mechanistic level. Chemosensory influences on food preference and selection, and their contribution to hyperphagia, are minimally understood. Food choice behaviors and their downstream impact on obesity management have yet to be rigorously studied using validated tools and methodologies, representing a critical knowledge gap that limits the development of targeted interventions.

Navigating the Challenging Prader-Willi Syndrome Pipeline

Over the past five years, the Prader-Willi syndrome (PWS) treatment landscape has advanced across several therapeutic fronts, with growth hormone therapy remaining a cornerstone of management while newer pharmacological strategies have entered clinical use. Long-term data on somatropin continue to affirm its role in improving body composition: a three-year study in young adults demonstrated a reduction in fat mass percentage SDS from 2.1 to 1.9, with stable lean body mass SDS and no growth hormone-related adverse events. A multicohort study in Japanese participants further corroborated these findings, showing that somatropin improved body composition in adults and enabled its maintenance in pediatric cohorts, meeting its primary endpoint based on a prespecified efficacy criterion for lean body mass change at Month 12. Across available literature, somatropin has demonstrated positive effects on muscle strength, exercise tolerance, cardiorespiratory function, and psychological outcomes, though most supporting studies remain uncontrolled and short-term in duration.

A landmark regulatory development in this period was the FDA approval of diazoxide choline extended-release (DCCR) tablets for the treatment of hyperphagia in adults and children aged four years and older with PWS. In a 16-week randomized withdrawal study, placebo-arm participants exhibited significantly greater worsening of hyperphagia (HQ-CT least square mean change: 7.6 vs. 2.6 with DCCR; P=0.0022). Long-term data extending to 52 weeks showed meaningful HQ-CT improvements (mean −9.9, p<0.0001), with greater benefit observed in patients with more severe baseline hyperphagia (HQ-CT >22). Beyond hyperphagia, DCCR was associated with significant reductions in aggression, anxiety, and compulsivity (all p<0.0001), favorable metabolic changes including reduced leptin, insulin, and insulin resistance alongside increased adiponectin (all p<0.004), and increased lean body mass (p<0.0001). The most common treatment-emergent adverse events were hypertrichosis, peripheral edema, and hyperglycemia, with a low discontinuation rate of 7.2%.

Investigational pipelines have also progressed, albeit with mixed outcomes. The CARE-PWS Phase 3 trial evaluated intranasal carbetocin, an oxytocin analog, in 130 participants aged 7–18 years across 24 academic medical centers; however, enrollment was prematurely halted due to the COVID-19 pandemic. While primary endpoints for HQ-CT and CY-BOCS did not achieve statistical significance overall, the 3.2-mg dose arm demonstrated nominally significant improvements in HQ-CT, PADQ, and CGI-C scores versus placebo, with improvements sustained during long-term follow-up. Separately, intensive weight management strategies including very-low-energy diets (VLED) and pharmacotherapy with agents such as phentermine-topiramate and liraglutide have been evaluated, yielding median weight losses of 14 kg, 17 kg, and 9 kg, respectively, over variable durations. While substantial weight loss was achievable in some individuals, only 5 of 13 who achieved ≥10% weight loss maintained that threshold at last follow-up, underscoring the persistent challenge of non-adherence and weight regain in this population.